PRQR Stock Overview
A biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
ProQR Therapeutics N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.94 |
52 Week High | US$3.29 |
52 Week Low | US$1.11 |
Beta | 0.30 |
1 Month Change | -3.00% |
3 Month Change | -4.43% |
1 Year Change | 10.23% |
3 Year Change | -68.04% |
5 Year Change | -84.20% |
Change since IPO | -86.83% |
Recent News & Updates
Recent updates
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01ProQR reports Q3 results
Nov 16Shareholder Returns
PRQR | US Biotechs | US Market | |
---|---|---|---|
7D | 1.6% | 0.7% | 1.2% |
1Y | 10.2% | 5.0% | 27.7% |
Return vs Industry: PRQR exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: PRQR underperformed the US Market which returned 27.7% over the past year.
Price Volatility
PRQR volatility | |
---|---|
PRQR Average Weekly Movement | 8.5% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PRQR's share price has been volatile over the past 3 months.
Volatility Over Time: PRQR's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 157 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.
ProQR Therapeutics N.V. Fundamentals Summary
PRQR fundamental statistics | |
---|---|
Market cap | US$155.16m |
Earnings (TTM) | -US$29.05m |
Revenue (TTM) | US$11.42m |
13.9x
P/S Ratio-5.5x
P/E RatioIs PRQR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PRQR income statement (TTM) | |
---|---|
Revenue | €10.56m |
Cost of Revenue | €0 |
Gross Profit | €10.56m |
Other Expenses | €37.40m |
Earnings | -€26.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.33 |
Gross Margin | 100.00% |
Net Profit Margin | -254.28% |
Debt/Equity Ratio | 12.5% |
How did PRQR perform over the long term?
See historical performance and comparison